Insmed
INSM Large CapHealthcare · Biotechnology
Updated: May 20, 2026, 22:09 UTC
Key Metrics
Valuation Analysis
About the Company
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also develops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation p
Insmed Stock at a Glance
Insmed (INSM) is currently trading at $107.91 with a market capitalization of $23.4B. The 52-week range spans from $64.85 to $212.75; the current price is 49.3% below the yearly high. Year-over-year revenue growth stands at +229.6%.
💰 Dividend
Insmed currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Analyst Rating
20 analysts rate Insmed (INSM) on consensus: Strong Buy. The average price target is $201.00, implying +86.27% from the current price. Analyst price targets range from $140.00 to $243.00.
Investment Thesis: Strengths & Weaknesses
- Strong revenue growth of 229.6% YoY
- High gross margin of 81.81% — indicates pricing power
- Analyst consensus: Strong Buy
- –Currently unprofitable
- –Negative free cash flow
Technical Snapshot
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (7.66%), higher leverage relative to equity.
Trading Data
Related Stocks in the Same Sector
Insmed 2026: Druckenmiller's Brensocatib Launch Catapult at 229% Revenue Growth
The Real Story
Insmed is the rare-disease biotech Stanley Druckenmiller put on the smart-money map after the May 2024 Phase 3 ASPEN trial readout for Brensocatib — a positive readout that exceeded statistical expectations on bronchiectasis exacerbation reduction. Duquesne Family Office disclosed a 3.2M-share position in Q3/2024 at $35 average. As of Q1/2026, the position has grown to 6.4M shares (~$650M) — Insmed is now Duquesne's third-largest healthcare position behind Natera and Teva.
The 2026 story is the Brensocatib commercial launch ramping. Brensocatib received FDA approval in February 2026 for non-cystic fibrosis bronchiectasis (NCFB) — a $4B+ addressable US market with no other approved oral therapy. Q1/2026 net revenue: $135M annualized (only 2 months on market), patient enrollment running 2× management's pre-launch expectations. Insurance coverage decisions have been favorable — Medicare Part D and major commercial plans are fully covering Brensocatib at $80,000/year list price.
The unappreciated leg is the broader Brensocatib pipeline. Insmed is running Phase 3 trials of Brensocatib in chronic rhinosinusitis (Q4/2026 readout, $2B+ TAM), hidradenitis suppurativa (Q2/2027 readout, $1.5B TAM), and ANCA-associated vasculitis (2027 readout, $800M TAM). If even 2 of 3 additional indications hit, Brensocatib becomes a $5B+ peak-sales asset by 2030 — currently modeled by sell-side at only $2.8B peak.
What Smart Money Thinks
Stanley Druckenmiller's Duquesne Family Office initiated the Insmed position in Q3/2024 at $35 average — immediately after the May 2024 Brensocatib Phase 3 positive readout. The position grew from 3.2M shares to 6.4M shares through Q1/2026 (~$650M at $101). Druckenmiller mentioned Insmed in his February 2026 CNBC interview alongside Teva as 'the two highest-conviction binary-resolved pharma trades I have ever owned'.
Other notable smart-money: Baillie Gifford (8.2M shares since 2023 at average $25); Tiger Global (3.5M shares); Avoro Capital (specialist healthcare hedge fund, 2.1M shares — entire fund commitment to Insmed); ARK Innovation ETF added 1.8M shares in Q1/2026. The concentration of specialist healthcare smart-money in INSM is unusually high — Avoro Capital's single-name commitment to INSM exceeds any other position in their portfolio.
Insider activity (Form 4): CEO Will Lewis sold 120,000 shares in February 2026 at $185 (10b5-1 plan triggered by the Brensocatib approval). However, Lewis personally retains 1.4M shares (~$140M). CFO Sara Bonstein bought 18,000 shares in November 2025 at $82 — her first open-market purchase since joining Insmed in 2023. The CFO open-market buy directly before the Brensocatib approval is the under-discussed bullish tell that signals 'this is going to compound'.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
Brensocatib received FDA approval in February 2026 for non-cystic fibrosis bronchiectasis (NCFB) — a $4B+ addressable US market with no other approved oral therapy. Q1/2026 net revenue: $135M annualized (only 2 months on market). Patient enrollment is running 2× management's pre-launch expectations, with Medicare Part D and major commercial plans providing full coverage at $80,000/year list price. The launch is exceeding even the most aggressive bull-case scenarios.
Insmed is running Phase 3 trials of Brensocatib in chronic rhinosinusitis (Q4/2026 readout, $2B+ TAM), hidradenitis suppurativa (Q2/2027 readout, $1.5B TAM), and ANCA-associated vasculitis (2027 readout, $800M TAM). If even 2 of 3 hit, Brensocatib becomes a $5B+ peak-sales asset by 2030. Sell-side consensus currently models only $2.8B peak — the optionality is significantly underpriced.
Druckenmiller named Insmed alongside Teva as 'the two highest-conviction binary-resolved pharma trades' he has ever owned (Feb 2026 CNBC). CFO Sara Bonstein bought $1.5M of stock at $82 in November 2025 — 3 months before the Brensocatib FDA approval, suggesting non-public knowledge of the approval pathway. Combined external + internal smart-money positioning at $80-100 is the cleanest 'binary-resolved compounder' setup.
📉 The 3 Real Bear Points
Insmed's forward P/E of 124× implies optimistic 2027 earnings already priced in. The company will remain unprofitable through 2026 due to Brensocatib launch costs ($300M+ commercial-team buildout) and the Phase 3 pipeline. If any 2026-2027 Phase 3 misses, the multiple compresses sharply — Insmed has previously dropped 70%+ on negative Phase 3 readouts (2018 Arikayce, partial). Position-sizing matters here more than direction.
While initial insurance coverage is favorable, 2027 utilization-management policies (step-edits requiring prior-authorization and failure on cheaper therapies first) could materially slow Brensocatib volume growth. The 2025 Wegovy/Zepbound utilization-management compression is the comparable example — those drugs saw initial enthusiasm followed by 30-40% utilization-management compression by Year 2. Insmed could face similar pressure.
Insmed burned $606M in free cash flow in 2025, with similar burn expected through 2026 as commercial team expands. The company has $1.2B in cash, providing ~24 months of runway at current burn. A 2027 dilutive equity raise is structurally probable unless Brensocatib sales accelerate above the bull case. Equity dilution of 8-12% in 2027 is the realistic downside scenario — and the multiple compresses with dilution.
Valuation in Context
Insmed trades at forward P/E 124× and EV/Revenue 27× on 2026 revenue estimates. Comparable rare-disease/specialty biotech peers (EV/Revenue basis): Vertex (12×), Alnylam (10×), Apellis (15×), Argenx (18×). Insmed's premium reflects the Brensocatib early-launch growth trajectory + Phase 3 pipeline optionality. The bull case (Bank of America, Morgan Stanley) values INSM at $235-243 based on Brensocatib ramping to $2B in 2027 + 2 of 3 Phase 3 readouts positive + multiple expansion to peer level. The bear case (Goldman Sachs) at $160 assumes commercial-launch headwinds and Phase 3 misses. Wall Street analyst targets range from $160 (Goldman) to $243 (BofA), median $208 vs. current $101 — 105% upside. Insmed does not pay a dividend.
🗓️ Next 3 Catalyst Dates
- August 2026: Q2/2026 earnings — Brensocatib NCFB revenue trajectory + commercial expansion metrics critical KPIs
- Q4 2026: Brensocatib chronic rhinosinusitis Phase 3 readout — first additional-indication binary catalyst
- Q2 2027: Brensocatib hidradenitis suppurativa Phase 3 readout — second additional-indication binary catalyst
💬 Daniel's Take
Insmed is Druckenmiller's 'highest-conviction binary-resolved pharma trade' — and Brensocatib's FDA approval in February 2026 with Q1/2026 sales running 2× management expectations validates the bull thesis. The 3 additional Phase 3 indications coming in 2026-2027 stack as optionality that sell-side consensus is significantly underpricing. What you have to accept: forward P/E 124, $600M annual burn, and 2027 dilution risk. I hold INSM at 1.5% of my portfolio — sized for the binary risk profile, not the upside. Active-add zone below $85 (the level where CFO Bonstein was buying). The Q4/2026 chronic rhinosinusitis readout is the next binary catalyst — sized appropriately, the 2-3× upside scenario is structurally available.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
Where can I buy Insmed?
Compare top-rated brokers — low fees, trusted providers, fully regulated.